;

Insights

Latest News

    Trending Topics

      Products

      Products


      Brand Protection

      IP Intelligence

      Litigation Analysis

      Case Management

      Nunc Orci


      Products Case Studies

      People

      Careers

      About

      Announcements

      • About Us
      • The Rouse Network
      • The Rouse Difference
      • Rouse Connect

      Grass Roots

      • Climate Change
      • Mitrataa
      • Rouse Cares

      Sanofi's TB patents dispute overflows to Indonesia

      Published on 29 Jan 2020 | 1 min read

      Indonesia may be getting caught up in a TB medicine dispute. Sanofi has filed numerous patents for medicines combining two APIs, rifapentine and isoniazid. Both APIs are out of patent protection globally. Sanofi patents include the combination of the drugs including as child formulations and film coated tablets. Some countries granted them, others objected. For example the patent for a film coated tablet and dispersible formulation was objected to in India as being a combination of two existing drugs so not patentable there.

      Sanofi’s strategy appears to have been to file multiple forms, but to accept that some may not be patented, in order to get others accepted. In Indonesia, the child formulations and film coated tablets patent was withdrawn in order to get the combination of isoniazid and rifapentine drugs accepted.

      Activists in India including Médecins Sans Frontières are particularly vociferous given TB is a serious problem there and there are concerns whether such countries can procure generic combinations of the two APIs if a patent is granted. Sanofi is coming under pressure to surrender all of its patents for these compounds and formulations.

      30% Complete
      Deputy CEO, Principal
      +62 811 870 2616
      Deputy CEO, Principal
      +62 811 870 2616
      ;